Liver Transplantation Market to Hit USD 2.4 Billion by 2033, CAGR at 6.2%

Trishita Deb
Trishita Deb

Updated · Jul 22, 2025

SHARE:

Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Learn more.
close
Advertiser Disclosure

At Market.us Media, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us Media. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

Overview

New York, NY – July 22, 2025: The global liver transplantation market is projected to reach approximately US$ 2.4 billion by 2033, up from US$ 1.3 billion in 2023. This growth reflects a steady CAGR of 6.2% from 2024 to 2033. Liver transplantation is a critical procedure used when chronic liver conditions progress to a life-threatening stage. It is most often performed for liver cirrhosis, hepatitis-related damage, liver cancer, and nonalcoholic fatty liver disease. The market includes all services and technologies supporting the transplant process, from surgery to patient recovery.

This market covers a wide range of components. It includes surgical services, post-operative care, immunosuppressive drugs, and diagnostic tools. Monitoring technologies play a key role in patient follow-up and in preventing organ rejection. The market is growing due to the rising prevalence of liver diseases and improvements in healthcare systems, especially in developed countries. High-income regions are seeing more successful transplant outcomes due to better infrastructure, early diagnosis, and advanced medical tools. These developments have expanded the patient base eligible for transplants.

According to the Organ Procurement and Transplantation Network, the U.S. recorded 10,660 liver transplants in 2023. This is an 11.9% increase from the 9,528 procedures in 2022. Deceased donor procedures dominated, while living donor transplants reached a record of 603 in 2022. It was the twelfth consecutive year of growth in deceased organ donations. These trends show the effectiveness of improved donor awareness and surgical progress. Enhanced techniques have helped reduce complications and improve survival rates, driving further growth in the transplantation space.

Despite these gains, supply does not meet demand. The Scientific Registry of Transplant Recipients reported 24,186 adult candidates on the waiting list in 2022. This was down 10.7% from 2012, yet 10,548 were still waiting by year-end. During the year, thousands of patients were added and removed, highlighting the fluctuating nature of the list. While transplant volumes rise, the gap between need and availability remains. This imbalance continues to shape the regulatory, clinical, and commercial strategies within the market.

Key market drivers include advanced surgical technologies and improved immunosuppressive therapies. Innovations in donor registration systems also support higher transplant success rates. Yet, challenges remain. These include high procedural costs, infection risks, and immune rejection. Such factors affect both clinical outcomes and market penetration. Increased investments in healthcare, especially in high-income countries, have helped expand access to liver transplants. However, solving the persistent donor shortage will be essential to meet growing demand and sustain long-term market momentum.
Liver Transplantation Market Size

Key Takeaways

  • According to analysts, the liver transplantation market is expected to grow from US$ 1.3 billion in 2023 to US$ 2.4 billion by 2033.
  • Experts highlight that liver transplantation surgery held the largest share in 2023, contributing to over 62% of the global market’s treatment segment.
  • Industry data shows hospitals were the top end-users in 2023, representing more than 51% of total liver transplantation-related healthcare services.
  • North America emerged as the leading region in 2023, accounting for over 30% of the global market and valued at approximately US$ 0.3 billion.

Regional Analysis

In 2023, North America led the global liver transplantation market with over 30% share, valued at approximately US$ 0.3 billion. This dominance is driven by advanced healthcare infrastructure, high public awareness, and favorable reimbursement frameworks. The rising prevalence of liver diseases, particularly cirrhosis and hepatitis C, has significantly increased demand for transplant services across the region. The United States plays a major role, with more than 9,000 liver transplants performed annually, according to the Organ Procurement and Transplantation Network. Growing investments in specialized transplant centers have further strengthened service access and market expansion.

Canada also contributes notably to regional growth, supported by strong government backing for liver disease treatment and organ donation initiatives. Organizations like the Canadian Liver Foundation run widespread awareness campaigns that encourage organ donation and promote liver health. North America’s continued leadership in the liver transplantation market is underpinned by its medical advancements, public-private collaboration, and policies that enhance treatment accessibility. These factors are expected to support the region’s sustained dominance in the years ahead.

Segmentation Analysis

In 2023, liver transplantation surgery dominated the treatment type segment, accounting for over 62% of the market share. This strong position is due to continuous advancements in surgical techniques, improved post-operative outcomes, and rising transplant demand. Enhanced survival rates and better healthcare infrastructure have further fueled the need for surgical interventions. Additionally, post-surgery anti-rejection therapies play a crucial role in ensuring transplant success. The growing use of targeted therapies and immunosuppressive drugs—such as Tacrolimus, Cyclosporine, and Sirolimus—has significantly boosted this segment. Emerging treatments and personalized medicine are also gaining ground, offering innovative solutions to improve long-term patient outcomes.

In terms of end users, hospitals led the market in 2023 with more than 51% share, driven by their advanced infrastructure and comprehensive care. Their ability to handle complex cases and offer multidisciplinary services makes them the preferred choice for liver transplant patients. Transplant centers followed closely, offering specialized, technology-driven care with streamlined transplant protocols. Ambulatory surgical centers (ASCs), while holding a smaller share, are gaining popularity for handling less complex procedures with cost-effective outcomes. Clinics and standalone medical units also contribute by expanding transplant services to underserved regions, supporting broader healthcare access and market growth.

Key Market Segments

By Treatment Type

  • Liver Transplantation Surgery
  • Post-Surgery Anti-Rejection Treatment
  • Cyclosporine
  • Tacrolimus
  • Sirolimus
  • Prednisone
  • Others

By End User

  • Hospitals
  • Transplant Centres
  • Ambulatory Surgical Centres
  • Others

Key Players Analysis

The liver transplantation market is shaped by leading innovators such as AlloSource, Conatus Pharmaceuticals, and Digna Biotech. AlloSource specializes in tissue preservation and regenerative solutions to improve graft viability, while Conatus focuses on developing non-surgical therapies like emricasan to delay transplant needs. Digna Biotech explores gene therapy and liver cell regeneration to enhance post-transplant recovery. These companies prioritize research and development and often form strategic collaborations to improve treatment success and address critical challenges like organ shortages and transplant rejection.

Additional key contributors include Dompé Farmaceutici and Isogenis Inc. Dompé develops biologics targeting rare liver diseases and offers supportive therapies for transplant care. Isogenis advances regenerative approaches, including bioengineered liver constructs, to reduce dependency on donor organs. Companies like Organogenesis, Astellas Pharma, and Pfizer also strengthen the market with innovations in graft materials, immunosuppressive treatments, and post-transplant care. Through partnerships and advanced research, these players are driving market growth, helping to meet the global demand for improved liver disease treatment and expanding transplant accessibility.

Market Key Players

  • Allosource
  • Conatus Pharmaceuticals Inc.
  • Digna Biotech S.L.
  • Dompe Farmaceutici S.p.A.
  • Isogenis Inc.
  • RedHill Biopharma Ltd.
  • Thompson Surgical
  • Integra Life Sciences
  • Baxter International Inc.
  • VirTech Bio

Emerging Trends

Living Donor Transplants Are Increasing

More people are choosing to donate a part of their liver while they are still alive. This is called a living donor transplant. It helps reduce the long waiting times for patients who need a new liver. Living donor procedures are becoming safer due to better surgical techniques. Hospitals are also improving donor and recipient matching. These changes are encouraging more families to consider donation. As awareness grows, this method is helping save more lives. It is especially helpful in countries where deceased donors are few. The trend is expected to grow with better education and outreach programs.

Regenerative Therapies Are Gaining Interest

Scientists are now exploring ways to repair the liver using new technologies. Regenerative medicine uses stem cells or lab-grown liver tissue to help the liver heal. These approaches may reduce the need for a full liver transplant in the future. Research is still in early stages, but the results look promising. Some therapies aim to regenerate damaged liver cells, while others try to create small, functional liver units. If successful, these therapies could help patients avoid major surgery. This trend shows how technology is opening new doors in liver care. It may become a real option in the next decade.

Minimally Invasive Surgery is Growing

Liver transplant surgery is becoming less invasive due to modern tools and robotic systems. These technologies help surgeons perform procedures with smaller cuts. This means patients heal faster and face fewer risks. Shorter hospital stays and lower infection rates are also benefits of this method. Robotic-assisted surgery is being used in top hospitals around the world. It allows for better precision and less trauma during the operation. Patients also feel less pain after surgery. As more hospitals invest in this technology, minimally invasive liver transplants are becoming more common. This trend will continue as innovation improves.

Improved Organ Preservation Techniques

Keeping a donated liver healthy before surgery is very important. New methods like machine perfusion are helping in this area. This technology pumps oxygen and nutrients through the liver while it’s outside the body. It keeps the organ working and reduces the chance of failure. Traditional storage uses ice, but it doesn’t work as well for long transport times. Machine perfusion gives doctors more time to assess the liver’s health. It also increases the number of livers that can be used. As more hospitals adopt this method, transplant success rates are improving. This is a major step forward.

Personalized Medicine is Being Applied

Every liver transplant patient is different. Doctors are now using personalized medicine to improve care. This means they study the patient’s genetic makeup and health history to plan the best treatment. It helps choose the right drugs and lowers the risk of rejection. Some patients need more support after surgery, while others recover faster. Personalized medicine allows for tailored care. This results in better survival rates and fewer side effects. Hospitals are using advanced software and tests to guide these decisions. As this trend grows, patients will benefit from safer and more effective transplant outcomes.

Use Cases

End-Stage Liver Disease Treatment

Liver transplantation is the only option for people with end-stage liver failure. Conditions like cirrhosis, chronic hepatitis B or C, and alcohol-related liver damage are common causes. These diseases slowly damage the liver until it stops working. Once this happens, a transplant becomes the only way to save the patient’s life. Each year, more than 10,000 people around the world undergo this surgery. It offers them a chance to live a longer and healthier life. With better screening and diagnosis, more patients are being identified in time. This use case remains the primary reason liver transplants are performed globally.

Liver Cancer Management

Liver transplants are also used to treat certain types of liver cancer. This is especially true for hepatocellular carcinoma in its early stages. If the cancer is small and hasn’t spread, doctors may recommend a transplant. Around 15–20% of liver transplants are done for cancer patients. The goal is to remove the diseased liver entirely and replace it with a healthy one. This improves both survival and quality of life. In many cases, transplant success rates for cancer patients are high. That’s why liver cancer is becoming a more recognized use case in transplant programs worldwide.

Pediatric Liver Transplants

Children with serious liver diseases, like biliary atresia, often need a transplant early in life. These rare conditions can be life-threatening if not treated in time. Pediatric liver transplants offer a long-term solution. Each year, about 500 to 700 children receive this surgery globally. Many of these operations use a part of a liver from a living adult, usually a parent. Children generally recover well and lead healthy lives after surgery. Specialized transplant teams focus on managing these cases with extra care. Pediatric transplants are vital for giving children a future free from life-threatening liver disease.

Emergency Transplants for Acute Failure

Acute liver failure happens suddenly and without warning. It may be caused by poisoning, infections, or overdoses of drugs like acetaminophen. In such emergencies, immediate liver transplantation is often the only way to save a life. These cases are rare but very serious. The patient’s condition can worsen in hours or days. Doctors must act fast to find a suitable donor. Emergency transplants make up a smaller share of total surgeries, but they are critical. Success depends on quick diagnosis, organ availability, and expert medical care. Hospitals with transplant capabilities are crucial for handling these urgent situations.

Re-Transplantation Cases

Sometimes, a liver transplant doesn’t work long term. The body may reject the new liver, or complications might develop later. In such cases, a second transplant is needed. This is called re-transplantation. Although not very common, it is a vital part of liver transplant programs. It shows how important regular check-ups and post-surgery care are for patients. Re-transplants are more complex and carry higher risks. Still, they offer patients another chance at life. This use case highlights the need for close monitoring and strong support systems after the first transplant. It’s a reminder that liver care doesn’t end after surgery.

FAQs Liver Transplantation

1. What is liver transplantation?
Ans:- Liver transplantation is a surgical procedure where a diseased liver is replaced with a healthy liver from a donor. It’s usually done for patients with liver failure or severe liver diseases.

2. Who qualifies for a liver transplant?
Ans:- Patients with end-stage liver disease, liver cancer, or acute liver failure may qualify. A transplant team evaluates medical history, severity, and eligibility.

3. What are the main causes of liver failure?
Ans:- Common causes include hepatitis B and C, alcoholic liver disease, nonalcoholic fatty liver disease, cirrhosis, and drug-related toxicity.

4. What is the difference between living and deceased donor liver transplants?
Ans:- A deceased donor transplant uses a whole liver from someone who has died. A living donor transplant uses a portion of a liver, usually from a relative or friend.

5. How long is the recovery time after liver transplantation?
Ans:- Most patients stay in the hospital for 2 to 3 weeks. Full recovery can take up to 6 months, depending on the individual’s health and complications.

6. What is the liver transplantation market?
Ans:- The liver transplantation market includes surgical services, post-operative care, donor matching systems, immunosuppressive drugs, and technologies used in transplant procedures.

7. What is driving the growth of the liver transplantation market?
Ans:- Key drivers include rising liver disease prevalence, improved surgical techniques, growing organ donation awareness, and advanced healthcare infrastructure.

8. Which region leads the liver transplantation market?
Ans:- North America leads due to high transplant volumes, advanced hospitals, and favorable reimbursement policies. Europe and Asia-Pacific are also growing rapidly.

9. Who are the key players in the liver transplantation market?
Ans:- Notable companies include AlloSource, Astellas Pharma, Pfizer, Organogenesis, Conatus Pharmaceuticals, Dompé Farmaceutici, and Digna Biotech.

10. What are the major challenges in the market?
Ans:- Organ donor shortages, high transplant costs, risk of post-surgical complications, and limited access in low-income countries are major hurdles.

Conclusion

The liver transplantation market is witnessing steady growth, driven by rising global liver disease cases, surgical advancements, and increasing awareness around organ donation. With a projected value of US\$ 2.4 billion by 2033 and a CAGR of 6.2%, the sector is expanding through improved surgical methods, personalized medicine, and innovations like regenerative therapies and organ preservation technologies. North America remains the market leader due to its advanced healthcare systems and strong donor networks. However, the persistent gap between organ supply and demand underscores the need for policy support, investment, and continued innovation to improve transplant access and patient outcomes worldwide.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

SHARE:
Trishita Deb

Trishita Deb

Trishita has more than 8+ years of experience in market research and consulting industry. She has worked in various domains including healthcare, consumer goods, and materials. Her expertise lies majorly in healthcare and has worked on more than 400 healthcare reports throughout her career.

Request a Sample Report
We'll get back to you as quickly as possible